As Redbiotec prepares for a Series A financing round to take the most advanced asset – immunotherapy for HSV2-associated genital herpes – into Phase I/IIa clinical trial, CEO Christian Schaub recently spoke with Mergermarket about company plans and visions.
Yao Cheng2020-03-26T09:53:39+01:00March 19th, 2020|
Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria
Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.